Borrmann type IV: An independent prognostic factor for survival in gastric cancer

Journal of Gastrointestinal Surgery

Volumn 12, Issue 8, 2008, Pages 1364-1369

  An, Ji Yeong ^a   Kang, Tae Ho ^a   Choi, Min Gew ^a   Noh, Jae Hyung ^a   Sohn, Tae Sung ^a   Kim, Sung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bormann type IV; Gastrectomy; Gastric cancer; Prognostic factor

Indexed keywords

ARTICLE; CANCER STAGING; CARCINOMA; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; KOREA; MALE; MIDDLE AGED; MORTALITY; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE; TIME;

CARCINOMA; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; KOREA; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 48849103263     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-008-0516-9     Document Type: Article

References (20)

1. Kwon SJ, Lee GJ. Clinicopathologic characteristics of Borrmann type IV gastric cancer. J Korean Surg Soc 2003;64(2):127-133.
2. Kim DY, Kim HR, Kim YJ, Kim S. Clinicopathological features of patients with Borrmann type IV gastric carcinoma. ANZ J Surg 2002;72(10):739-742.
3. Otsuji E, Kuriu Y, Okamoto K, Ochiai T, Ichikawa D, Hagiwara A, Yamagishi H. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 2004;188(3):327-332.
4. Yook JH, Oh ST, Kim BS. Cliniopathological analysis of Borrmanntype IV gastric cancer. Cancer Res Treat 2005;37:87-91.
5. Kodera Y, Yamamura Y, Ito S, Kanemitsu Y, Shimizu Y, Hirai T, Yasui K, Kato T. Is Borrmann type IV gastric carcinoma a surgical disease? An old problem revisited with reference to the result of peritoneal washing cytology. J Surg Oncol 2001;78(3):175-181. (discussion 181-172).
6. Hamy A, Letessier E, Bizouarn P, Paineau J, Aillet G, Mirallie E, Visset J. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg 1999;84(4):337-343.
7. Koyama T, Yashiro M, Inoue T, Nishimura S, Hirakawa YSCK. TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 2000;16(2):355-362.
8. Mahara K, Kato J, Terui T, Takimoto R, Horimoto M, Murakami T, Mogi Y, Watanabe N, Kohgo Y, Niitsu Y. Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 1994;69(4):777-783.
9. Zhou YN, Xu CP, Han B, Li M, Qiao L, Fang DC, Yang JM. Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World J Gastroenterol 2002;8(6):987-993.
10. Shino Y, Watanabe A, Yamada Y, Tanase M, Yamada T, Matsuda M, Yamashita J, Tatsumi M, Miwa T, Nakano H. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995;76(11):2193-2201.
11. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005;96(6):323-332.
12. Tanigawa N, Amaya H, Matsumura M, Lu C, Iki M. Association between tumor angiogenesis and Borrmann type 4 carcinomas of the stomach. Oncology 1998;55(5):461-467.
13. Otsuji E, Yamaguchi T, Sawai K, Sakakura C, Okamoto K, Takahashi T. Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma. Am J Gastroenterol 1999;94(2):434-437.
14. Ryu JH, Yook JH, Kim BS, Oh ST, Jung ST, Choi WY. Clinicopathologic characteristics and prognostic factors of long-term survivors of Borrmann type 4 gastric cancer. Korean J Gastroenterol 2003;41:9-14.
15. Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 2004;10(14):4885-4892.
16. Sasaki T, Koizumi W, Tanabe S, Higuchi K, Nakayama N, Saigenji K. TS-1 as first-line therapy for gastric linitis plastica: historical control study. Anticancer Drugs 2006;17(5):581-586.
17. Nakamura K, Yashiro M, Matsuoka T, Tendo M, Shimizu T, Miwa A, Hirakawa K. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006;131(5):1530-1541.
18. Akamo Y, Takeyama H, Funahashi H, Yamamori Y, Yamamoto M, Teranishi F, Manabe T. Efficacy of intraperitoneal chemotherapy for advanced Borrmann type IV gastric carcinoma. Gan To Kagaku Ryoho 2002;29(12):2184-2187.
19. Kunisaki C, Shimada H, Nomura M, Matsuda G, Otsuka Y, Ono H, Akiyama H. Therapeutic strategy for scirrhous type gastric cancer. Hepatogastroenterology 2005;52(61):314-318.
20. Ikeguchi M, Yamamoto O, Kaibara N. Management protocol for scirrhous gastric cancer. In Vivo 2004;18(5):577-580.